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Abstract
Background: It is well known progesterone can have anxiolytic-like effects in animals in a number of different behavioral
testing paradigms. Although progesterone is known to influence physiology and behavior by binding to classical
intracellular progestin receptors, progesterone’s anxiety reducing effects have solely been attributed to its rapid non-
genomic effects at the GABAA receptor. This modulation occurs following the bioconversion of progesterone to
allopregnanolone. Seemingly paradoxical results from some studies suggested that the function of progesterone to reduce
anxiety-like behavior may not be entirely clear; therefore, we hypothesized that progesterone might also act upon progestin
receptors to regulate anxiety.
Methodology/Principal Findings: To test this, we examined the anxiolytic-like effects of progesterone in male rats using the
elevated plus maze, a validated test of anxiety, and the light/dark chamber in the presence or absence of a progestin
receptor antagonist, RU 486. Here we present evidence suggesting that the anxiolytic-like effects of progesterone in male
rats can be mediated, in part, by progestin receptors, as these effects are blocked by prior treatment with a progestin
receptor antagonist.
Conclusion/Significance: This indicates that progesterone can act upon progestin receptors to regulate anxiety-like
behavior in the male rat brain.
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Introduction
Progesterone (P) can have anxiolytic-like effects in animals in a
number of behavioral paradigms [1–6]. P is known to influence
physiology and behavior by binding to classical intracellular
progestin receptors (PR), which in turn can act at the genome to
regulate gene expression [7–9]. The anxiolytic-like actions of P are
believed to occur mainly following its conversion by 5a-reductase
to one of its ring A reduced metabolites, 3a-hydroxy-5a-pregnan-
20-one (allopregnanolone) [10,11]. The effects of allopregnano-
lone occur in a rapid non-genomic membrane-mediated manner
[11,12], as it allosterically modulates GABAA receptors [13,14],
and it is through this interaction that allopregnanolone has its
anxiety-reducing effects on behavior [2,15–17].
Different approaches have been used to examine the relative
importance of P versus allopregnanolone in reducing anxiety-like
behavior. Some of these studies have uncovered results inconsis-
tent with the contention that there is a single pathway by which
anxiety is reduced. While one study utilizing female progestin
receptor knockout (PRKO) mice did report anxiolytic-like effects
of P [18], another study reported that male PRKO mice displayed
more anxiety-like behavior in the elevated plus maze. These
animals spent significantly less time in the open arms compared to
their wild type background strain [19]. These data suggest that PR
may play some role in regulating anxiety-like behaviors in males. If
reduction in anxiety-like behavior is only accomplished by
neurosteroid action in the brain, then mice containing the PRKO
mutation should not have altered anxiety levels. On the contrary,
it appears that the absence of PR in these mice leads to more
anxiety-like behavior compared to their wild type controls,
suggesting that PR might be involved in reducing anxiety-like
behavior.
Further support comes from studies that block 5a-reductase.
This treatment interferes with the production of allopregnanolone.
Mice deficient in this enzyme still showed anxiolytic-like behavior
in response to P within the elevated plus maze, suggesting that P
was still reducing anxiety-like behavior through some mechanism
other than its conversion into allopregnanolone [20]. Similarly,
lactating females, that have endogenously high levels of P, still
showed less anxiety-related behavior than control rats even after
treatment with an inhibitor of 5a-reductase, [21]. In this
experiment, however, the 5a-reductase inhibitor was effective, as
the turnover of P to allopregnanolone was significantly reduced.
Still anxiety-related behavior was low. These data suggest that an
additional pathway to regulate anxiety may exist, a pathway which
does not necessitate the conversion of P to its neuroactive
metabolites, and in which PR appear to play some role in
regulating anxiety-like behavior.
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3606In the current study, we aimed to test the hypothesis that P can
modulate anxiety-like behavior partly by acting upon PRinthe male
brain. Therefore, we examined the anxiolytic-like effect of P in the
presence or absence of the PR antagonist RU-486 using the elevated
plus maze, a validated test of anxiety [22,23], and the light/dark
chamber. We present evidence here to suggest that, in male rats, the
anxiolytic-like effects of P are indeed mediated, in part, by its actions
at the PR, as the anxiolytic-like actions of a physiologically-relevant
dose of P can be blocked by a PR antagonist.
Materials and Methods
This research was approved by the University of Wisconsin
Animal Care and Use Committee.
Animals
Adult male Sprague Dawley rats from our breeding colony
(400–600 g; breeders from Charles River Labs, Inc., Wilmington,
MA) were housed under a 12:12 light/dark cycle (lights off at
1100 h) with food and water available ad lib. As previous studies
have shown that progestogens can reduce endogenous levels of T
by directly inhibiting testicular steroidogenesis [24–27],rats were
castrated at approximately 3 months of age and implanted with
s.c. SilasticH implants (2.5 cm long, 1.5 mm inner diameter,
2.4 mm outer diameter, Dow Corning Corp. Midland, MI) filled
with testosterone (T).
Elevated plus maze
The elevated plus maze, a validated and widely used test of anxiety
in rodents [22,23], consists of 2 opposing runways, one open and one
closed, each measuring 100 cm in length and constructed of black
Plexiglas. Each arm of the closed runway is fitted with 39 cm high
Plexiglas walls on either side of the runways. The maze stands 50 cm
off the floor. The rats were placed in the center of the maze, where
the two arms intersect, facing an open arm. The animal’s behavior in
the maze was recorded for 5 minutes with a video camera connected
to a DVD player for later behavioral observation. DVD recorded
material was converted to MPEG format using VideoWaveH
Professional (Roxio, a division of Sonic Solutions, Novato CA) and
then analyzed using The ObserverH (Noldus Information Technol-
ogies, Wageningen, The Netherlands) by an experimenter blind to
the treatment groups. Parameters quantified were the number of
entriesintothe openandclosed arms,and totaltimespent intheopen
and closed armsand the center chamber. An entry was counted when
all four paws crossed into a certain portion of the maze.
Light/dark chamber
The light/dark chamber consists of a polycarbonate chamber that
is divided into one lighted chamber (39635 cm) and one darkened
chamber (39625). A piece of polycarbonate made to be opaque is
used to separate the light and dark sides of the chamber via insertion
into specially crafted guides to ensure a tight fit across the entire
width of the chamber. There is also an opening on the lower edge of
this insert (5610 cm) so the animal can move freely from one part of
the chamber to the other. The dark side of the chamber is
constructed of polycarbonate that is made to be opaque and this side
ofthe chamberisequippedwith an opaque lid.Awhite incandescent
light is situated above the light side of the chamber. The walls of this
side of the chamber are constructed of clear polycarbonate. The
animal was placed in the middle of the light side of the chamber
facing away from the opening toward the darkened side. A cross
from one compartment to the otherwasrecordedwhenall fourpaws
were in one compartment. The animals were observed in the
chamber for 5 minutes by an experimenter blind to the treatment
groups. Parameters quantified were latency to cross over to the dark
compartment of the chamber, and total amount of time spent on the
lit side of the chamber.
Data analysis
Statistical comparisons were carried out using Sigma Stat
statistical software for Windows v3.11 (Systat Software, Inc., Point
Richmond, CA). Data were compared with a One-Way ANOVA,
and further analyzed using the Fisher LSD Method. The level of
significance was set at p,0.05.
Treatment
Six weeks following surgery rats received s.c. injections of either
RU-486 (Sigma-Aldrich, St Louis, MO; 5 mg per animal) or vehicle
once daily for 3 days. On each of these days, 2 hours following the
RU-486 or vehicle injection animals received an injection of either P
(Sigma-Aldrich, St Louis, MO; 1 mg per animal) or sesame oil. The
dosage of RU-486 used was chosen because a dose response study
[28]indicated that this dosewas successful at blocking theeffects ofP
on behavior in female rats and guinea pigs. Also, in a study that
examinedtheanti-glucocordicoidpropertiesofthesamedoseofRU-
486 as has been used in the current experiment, cortisol treatment
given simultaneously with RU-486 was not able to prevent RU-486
from blocking P-facilitated behavior [29]. These data suggest that
this dose of RU-486 is blocking P-induced behavior by interfering
with the activation of PRs. The dosage of P was chosen because it
yields physiological levels of P that are observed following stress in
male rats [30,31], and is sufficient to induce sexual behavior in
female rats [32,33]. Four hours after the final P injection animals
weretested intheelevated plusmazeand light/darkchamberduring
the dark phase of the light cycle under dim red light.
Enzyme Immunoassay (EIA)
At least 500 ul of blood was collected from treated animals and
centrifuged at ,9700 RPMs or 10,000 gs for 10 minutes. Next,
serum was removed and stored in a clean tube at 220uC until used
in T or P EIA (Cayman Chemical Company, Ann Arbor, MI). Both
EIAs are based on the competition between the steroid of interest
and steroid-acetylcholinesterase conjugate for a limited number of
steroid specific binding sites. T or P standards were prepared
according to the manufacturer’s instructions. Following the
preparation of standards, these and the serum samples from our
treated animals were loaded into a 96-well plate, as well as the
necessarycontrols. Next, the T- orP-acetylcholinesterasetracerwas
added to most of the wells followed by addition of the T or P
antiserum to most of the same wells. The plate was then left to
incubate for 1 hour for the P assay and 2 hours for the T assay at
room temperature on an orbital shaker. After this incubation, the
contents ofthe plate werediscarded andthe plate wasrinsed 5 times
with wash buffer supplied by the manufacturer. Following these
rinses, Ellman’s Reagent, the developing reagent supplied by the
manufacturer,was added to the empty wells.The platewas thenleft
to develop in the dark while placed on an orbital shaker. The
developing process takes about 1 hour or until the absorbance of
the maximum binding wells equal 0.3 A.U. Following the
developing process, the plate is read at a wavelength between 405
and 420 nm with a plate reader. All samples for hormone
measurement were quantified in the same assay. The assay
specificity is 100% for T and P, respectively. The intra-assay
coefficient for each assay was 9.1% for the T and 8.5% for the P
assay, respectively. The detection limit of each assay was 6 pg/ml
and 10 pg/ml for the T and P assay, respectively. Results were
calculated using a computer spreadsheet program provided by
Cayman Chemicals (www.caymanchem.com/eiatools/promo/kit).
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The effect of RU-486 on the anxiolytic-like effect of P in
the elevated plus maze
As expected, P treatment reduced the anxiety-like behavior of
male rats in the elevated plus maze (p=0.019; Fig. 1a). Post hoc
analysis further revealed that the group of animals that were
pretreated with vehicle followed by P spent a larger percent of time
exploring the open arms of the maze. There were no differences in
percent open arm exploration in any of the other groups. In
addition, as might be expected, the percent of time spent exploring
the closed arms was decreased (p=0.001; Fig. 1b) in males pre-
treated with vehicle followed by P compared to all other groups.
There were no differences in percent closed arm exploration in
any of the other groups. More importantly, however, all of the
anxiolytic-like actions of P in male rats were blocked by prior
treatment with the PR antagonist, RU-486 (Fig. 1a and b). There
was no difference in the total number of arm entries in each of the
groups (p=0.06 Table 1).
The effect of RU-486 on the anxiolytic-like effect of P in
the light/dark chamber
There was a significant effect of treatment on time spent on and
latency to enter the light side of the light/dark box (p=0.006;
Fig. 2; p=0.01; Table 1, respectively). Vehicle plus P treated
animals spent more time on the light side of the chamber than
males in any of the other treatment groups. There were no
differences in time spent on the light side of the chamber in any of
the other groups. In addition, animals pre-treated with vehicle
followed by P also had longer latencies to cross over to the dark
side of the chamber compared with all the other groups tested.
There were no differences in latency to cross over to the dark side
in any of the other groups. More importantly, post hoc
comparisons indicate that the anxiolytic-like actions of P in male
rats were blocked by prior treatment with the PR antagonist, RU-
486 (Fig. 2 and Table 1).
Hormone levels
The levels of T assayed in our animals was in the range of 1.5–
2.5 ng/ml. This level is within the normal range for adult male
rats [34]. The levels of T found in each of the treatment groups
was similar (p=0.194; Fig. 3a).
The levels of P was significantly increased by P treatment
(p=0.001; Fig. 3b). The animals not treated with P, the vehicle-oil
and the RU-486-oil groups, had levels of P that were in the range
of typical levels for males of this age [30,31]. The level of P in the
vehicle-oil and in the RU-486-oil groups was 2.26.2 ng/ml and
1.46.2 and 2.296.26 ng/ml, respectively. The animals treated
with P had much higher levels of P; however, these levels were
similar to the physiological levels observed in animals that are
exposed to stress paradigms [30]. The level of P in the vehicle-P
and in the RU-486-P groups was 8.96.4 and 7.760.7 ng/ml,
respectively.
Figure 1. The effect of P and RU-486 on the percent time spent
in the open and closed arms of the elevated plus maze. (A),
Animals pre-treated with vehicle (Veh) and then treated with
progesterone (Prog) spent a significantly longer percentage of time in
the open arms compared to all groups. This effect was blocked in the
animals pre-treated with RU-486 (RU) and treated with progesterone.
(B), Percent time spent in the closed arms of the elevated plus maze.
Animals pre-treated with vehicle and then treated with progesterone
spent a significantly shorter percentage of time in the closed arms of
the maze compared to all other groups. (N=7–9 animals per group;
Bars indicate mean6SEM; * indicates a significant difference between
animals treated with vehicle and progesterone and all other groups
P,0.05).
doi:10.1371/journal.pone.0003606.g001
Table 1. Data are separated by task.
Task Variable V-O V-P RU-P RU-O
Light/dark chamber Latency to enter the dark chamber (sec) 15.9464.49 26.0962.72* 13.9462.42 11.4561.87
Elevated Plus Maze # Total Entries 3.126.51 4.756.81 6.06.94 3.86.61
% Time Open 6.863.10 42.33615.89* 16.1964.9 3.4061.9
%Time Closed 77.91611.15 25.99614.52* 72.6869.47 84.1067.19
Light/dark chamber; animals pre-treated with vehicle (Veh) and then treated with progesterone (Prog) had the longest latency to enter the dark side of the chamber.
Elevated plus maze; there was no difference in total number of entries in any of the groups. (N=6–9 animals per group; Data shown are mean6SEM; *indicates a
significant difference between Veh-Prog and all other groups (p,0.01).
*indicates a significant difference between animals treated with vehicle and progesterone (V-P) and all other groups (p,0.01). N=6–9 animals per group. V-O, Vehicle-
Oil; RU-P, RU-486-Progesterone; RU-O, RU-486-Oil.
doi:10.1371/journal.pone.0003606.t001
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We report that P can have anxiolytic-like actions on behavior in
male rats in two widely accepted tests of anxiety. Also, these actions
can be virtually eliminated by blocking PR. Our results indicate that
treatment with P decreases open arm avoidance on the elevated plus
maze and increases the amount of time spent on the light side of a
light/dark chamber. Importantly, prior treatment with the PR
antagonist RU-486 blocks this anxiolytic-like behavior. We do not
believe our effects can be attributed to antagonism of the
glucocorticoid receptor, as corticosterone has the opposite effects
on anxiety behavior as P [35]. We also reportthat P levels inanimals
that were treated with P were, as might be expected, significantly
higher than the levels observed in our non-P treated control groups
and that T levels are unaffected by treatment. Our behavioral results
suggest that P acts on PR to reduce anxiety-related behavior in male
rats. While both of our P-treated groups had physiological relevant
levelsof circulating P,theanxiolyticactionsofP wasblockedinthose
males pretreated with the PR antagonist RU-486. If reductions in
anxiety-like behavior were solely a result of P metabolites acting on
GABAA receptors, both groups treated with P regardless of their
pretreatment would still have shown a reduction in anxiety-like
behavior, however they did not. Our data are also inagreement with
data which have shown that P can function to influence a single
behavior by activating both PR dependent and GABA receptor
mediated pathways [17,36–39].
PR dependent, or genomic, versus GABA receptor mediated, or
non-genomic, mechanisms for steroid hormone action have been
reported in modulating lordosis behavior, a measure of sexual
receptivity, in female hamsters [36]. Sexual receptivity in female
rodents is under the genomic control of systemic administration of
sequential estrogen (E) and P [40]. Also, sexual receptivity can be
facilitated non-genomically by GABAergic drugs implanted locally
into specific brain areas [41]. Data from a series of experiments that
examined genomic versus non-genomic regulation of lordosis
behavior, suggest that P implanted into the ventromedial hypothal-
amus (VMH), and either P or its neuroactive metabolites implanted
into the ventral tegmental area (VTA) facilitate lordosis [42,43]. In
the PR rich VMH, P functions in a genomic manner; in the VTA
where PRare notasplentiful, themetabolites of Plikelyfunction ina
membrane-mediatednon-genomicmanner.Basedonthesedataand
the data from the experiment presented here, we hypothesize that P
may regulate anxiolytic-likebehavior inmale rats ina manner that is
consistent with a dual pathway. We suggest that in one pathway, P
influences anxiety following its metabolism to neuroactive steroids
and subsequent modulation of the GABAA receptor, indeed there is
an overwhelming amount of evidence for this mechanism [44]. An
additional, perhaps complementary, pathway may also exist by
which P influences anxiety by interacting with PR.
A previous study showed that the PR antagonist RU-486 given
to female rats did not block the anxiolytic-like effects of P [16].
These data provided support for the hypothesis that P modulates
GABAA receptors following its conversion to neuroactive steroids.
There are some differences between that study and ours that may
help to explain the discrepancies between our findings and theirs.
One difference may be that we used males in our studies and the
previous experiment used females, and PR function may differ
between the sexes. Also, both studies used doses of P and RU-486
that were similar, however, the females in the previous experiment
were tested in the elevated plus maze 4 hours after 1 P treatment.
In the current experiment, we treated animals with P and/or RU-
486 for three days. P can rapidly, in a non-genomic manner,
influence anxiety via GABAA receptors [10], perhaps then over a
longer period of time, P can influence anxiety through
Figure 3. The effect of P and RU-486 on plasma testosterone
and progesterone levels in male rats. (A), Testosterone levels were
statistically the same in each treatment group. All animals in this
experiment were castrated and implanted with testosterone-filled
capsules. (B), Progesterone levels were higher in both groups of
progesterone-treated animals compared to control groups. (Bars
indicate mean6SEM; * indicates a significant difference between
groups (p=0.001).
doi:10.1371/journal.pone.0003606.g003
Figure 2. The effect of P and RU-486 on time spent in the light
side of a Light/Dark chamber. Animals pre-treated with vehicle
(Veh) and then treated with progesterone (Prog) spent a significantly
longer amount of time on the light side of the chamber than all other
groups. This effect was blocked by pre-treatment with RU-486 (RU).
(N=6–7 animals per group; Bars indicate mean6SEM; * indicates a
significant difference between animals treated with vehicle and
progesterone and all other groups (p=0.006).
doi:10.1371/journal.pone.0003606.g002
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genomic versus non-genomic action to occur is unclear, it is often
agreed upon that genomic action can be measured in hours or
days while non-genomic action can take place in seconds and/or
minutes [45,46]. Indeed, we have shown that systems regulated by
P are only influenced by P after multiple days (3–5) of treatment
[47]. Based on this reasoning, it may be the time course of
treatment that holds the answer to the differential results presented
in the past and the data we present here.
A potential mechanism by which P may be acting on other
systems in the brain may be through modulation of the vasopressin
system. A role for altered transmission in the vasopressin system in
mediating anxiety-related behaviors has been supported in
numerous studies [48–51]. We have recently shown that treatment
of male rats with P reduces the expression of vasopressin protein in
portions of the vasopressin system [52]. These portions of the
vasopressin system are highly sexually dimorphic (i.e., males have
56as many cells and fibers in these areas as females), and steroid
responsive [53,54]. As P treatment can reduce vasopressin
expression in the male brain, and reduced vasopressin action in
the brain results in decreased anxiety-like behavior, the effect of P
on anxiety-related behavior in male rats may be through
modulation of the vasopressin system.
The distribution of PR in brain regions that are involved in
anxiety is consistent with the idea that P may regulate anxiety by
binding to intracellular PR. Indeed, the distribution of PR in both
the male and female rat brain has been well described. A number
of techniques, from binding assay to PCR, have been used to
localize PR in the brain [47,55–58]. Areas classically associated
with reproduction, the preoptic area, the ventromedial, dorsome-
dial and arcuate nucleus of the hypothalamus all contain PR. In
addition, PR has been reported in the olfactory bulb, frontal
cortex, hippocampus, cerebellum and brainstem. Areas that have
been implicated in the neural basis of fear, stress, and anxiety [59]
also contain PR [47]. For example, the bed nucleus of the stria
terminalis contains especially high numbers of PR and the
amygdala, as well, contains PR immunoreactivity. These data
suggest that P could act on PR in areas that play a large role in
modulating anxiety-like responses.
The data presented here add to the growing body of knowledge
as to the mechanisms by which P influences anxiety. Much of the
data concerning the effect of P on anxiety have shown that P’s
effects are highly dependent upon dose. It is important to note that
many of the studies investigating the anxiolytic actions of P use
supraphysiological doses. In most of these studies, when dose is
adjusted for species and size of animal, single doses range from
about 5 to 50 times higher [1,10,18,60] than the treatment course
of P used in the current study. We chose to keep the current dose
low, as male rats tend to have an average level of about 1.5–
2.0 ng/ml circulating P [30,31]. The dose of P used in our study
results in physiological levels of serum P levels in males that
resemble those of males enduring stress [30]. It is important to
note, however, that the elevated levels of P seen in our animals
were a result of 3 days of P treatment; a longer amount of time
than elevated P levels seen in stress. Higher endogenous levels of P
are coincident with higher levels of neurosteroids in the brain and
in the circulation [4], and it therefore stands to reason that
treatment with high doses of P result in higher levels of P
metabolites. These higher levels of metabolites may have a more
potent effect at GABAA receptors. Indeed, dose response studies
have shown that larger doses of P metabolites can have increasing
anxiolytic-like effects [1,15]. Taken together, it is conceivable that
our animals may have had low levels of brain neurosteroids
following treatment with low P doses, as is evidenced by
physiological circulating levels of P.
In summary, our data suggest an additional pathway by which P
can regulate anxiety-like behavior in males. They also support a
physiologically and behaviorally relevant role for P in the male
brain. While the data indicating a role for neuroactive steroids in
the reduction of anxiety-like behavior are quite compelling and by
no means in question, the data presented here suggest that there
may be an important role for PR in the reduction of anxiety-like
behavior in male rats.
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